RAPT Therapeutics Inc. Announces Upcoming Phase 2 Results for Chronic Spontaneous Urticaria Candidate

RAPT Therapeutics Inc. (NASDAQ: RAPT), a clinical‑stage immunology‑focused biopharmaceutical company headquartered in South San Francisco, has scheduled the release of topline data from a Phase 2 trial of its investigational compound RPT904 (also known as JYB1904). The study, conducted by Shanghai Jeyou Pharmaceutical Co., Ltd., evaluated the safety and efficacy of RPT904 in patients suffering from Chronic Spontaneous Urticaria (CSU), a debilitating allergic inflammatory disorder.

Key Details of the Upcoming Release

  • Event Timing:

    • Pre‑market press release and webcast: Monday, October 20, 2025.
    • Webcast conference call: 8:30 a.m. ET on the same day, accompanied by a slide presentation and a live Q&A session.
    • Participants: Investors, analysts, and interested parties can pre‑register online to receive a telephone number and unique passcode for the call.

  • Source of Data: The Phase 2 study was conducted under the auspices of Shanghai Jeyou Pharmaceutical Co., Ltd., formerly Shanghai Jemincare Pharmaceutical Co., Ltd. RAPT Therapeutics will summarize the findings in a public filing, with the expectation that the data will shed light on the drug’s clinical profile and potential for regulatory approval.

Company Context

RAPT Therapeutics specializes in immunology, small‑molecule drug discovery, and computational biology services aimed at treating cancer and allergic inflammatory diseases. The company’s market capitalization stands at approximately $481 million USD, trading on the Nasdaq in U.S. dollars. Its recent share price, as of October 16, 2025, closed at $29.34, positioned within a 52‑week range that peaked at $32.35 and dipped to $5.664. The firm’s price‑to‑earnings ratio is currently negative, reflecting its status as a research‑stage entity without sustained earnings.

Implications for Stakeholders

The forthcoming Phase 2 results are a pivotal milestone for RAPT Therapeutics. Positive efficacy signals, coupled with an acceptable safety profile, could accelerate the company’s pipeline progress toward regulatory submission and eventual commercialization. Investors and market observers will closely monitor the data to gauge the therapeutic’s potential impact on the CSU treatment landscape, which remains underserved by current options.

Next Steps

Stakeholders are encouraged to attend the scheduled webcast to receive real‑time insights and engage with RAPT’s management during the Q&A segment. The company’s detailed slide deck will provide a comprehensive overview of the study design, patient demographics, primary and secondary endpoints, and any emerging safety concerns.

As RAPT Therapeutics prepares to disclose these critical findings, the biopharmaceutical sector will be watching to determine whether RPT904 can emerge as a viable therapeutic candidate for CSU and potentially broaden the firm’s immunology portfolio.